R

RayzeBio

Biotech & Life Sciences · San Diego, United States · Founded 2020 · IPO 2023

RayzeBio is a vertically integrated radiopharmaceutical therapeutics company focused on improving cancer patient survival through the development of targeted, innovative drugs that harness the power of radioisotopes. The company operates in the oncology market, serving cancer patients with solid tumors, including metastatic disease. RayzeBio's business model involves the discovery, preclinical evaluation, and clinical development of radiopharmaceutical drug candidates. The company makes money by advancing its drug candidates through clinical trials and eventually bringing them to market, where they can be used to treat cancer patients. RayzeBio has built a diverse portfolio of drug candidates ranging from early discovery to late-stage clinical programs, leveraging over 500 in vivo experiments and a systematic, data-driven approach to drug development. The company aims to selectively kill cancer cells by delivering radioisotopes intravenously in a targeted manner directly to tumors. Keywords: radiopharmaceutical, therapeutics, oncology, cancer, radioisotopes, drug development, clinical trials, solid tumors, metastatic disease, targeted therapy.